

Accepted Manuscript

The selective 5-HT₆ Receptor Antagonist SLV has Putative Cognitive- and Social Interaction Enhancing Properties in Rodent Models of Cognitive Impairment

N.M.W.J. de Bruin, A. van Loevezijn, K.M. Wicke, M. de Haan, J. Venhorst, J.H.M. Lange, L. de Groote, M.A.W. van der Neut, J. Prickaerts, E. Andriambeloson, A.G. Foley, M. van Drimmelen, M. van der Wetering, C.G. Kruse


PII: S1074-7427(16)30094-6
DOI: <http://dx.doi.org/10.1016/j.nlm.2016.06.020>
Reference: YNLME 6470

To appear in: *Neurobiology of Learning and Memory*

Received Date: 15 March 2016
Revised Date: 27 May 2016
Accepted Date: 21 June 2016

Please cite this article as: de Bruin, N.M.W.J., van Loevezijn, A., Wicke, K.M., de Haan, M., Venhorst, J., Lange, J.H.M., de Groote, L., van der Neut, M.A.W., Prickaerts, J., Andriambeloson, E., Foley, A.G., van Drimmelen, M., van der Wetering, M., Kruse, C.G., The selective 5-HT₆ Receptor Antagonist SLV has Putative Cognitive- and Social Interaction Enhancing Properties in Rodent Models of Cognitive Impairment, *Neurobiology of Learning and Memory* (2016), doi: <http://dx.doi.org/10.1016/j.nlm.2016.06.020>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



The selective 5-HT₆ Receptor Antagonist SLV has Putative Cognitive- and Social Interaction Enhancing Properties in Rodent Models of Cognitive Impairment

N.M.W.J. de Bruin^{1*§}, A. van Loevezijn^{1□}, K.M. Wicke², M. de Haan^{1§§}, J. Venhorst^{1‡}, J.H.M. Lange^{1‡‡}, L. de Groote¹, M.A.W. van der Neut^{1□□}, J. Prickaerts³, E. Andriambeloson⁴, A.G. Foley⁵, M. van Drimmelen^{1‡‡}, M. van der Wetering^{1‡‡‡}, C.G. Kruse^{1□□□}

¹Abbott Healthcare Products BV (formerly Solvay Pharmaceuticals), C.J. van Houtenlaan 36, 1381 CP Weesp, The Netherlands

²AbbVie Deutschland GmbH & Co. KG, Dept. of Pharmacology, Knollstr., 67061 Ludwigshafen, Germany

³Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, PO Box 616, 6200 MD Maastricht, the Netherlands

⁴Neurofit SAS, Bioparc, Parc d'Innovation, Boulevard Sebastien Brant 67400 Illkirch, France

⁵Berand Ltd., NovaUCD, Belfield Innovation Park, University College Dublin, Dublin 4, Ireland

Corresponding author *

§ Current Address:

Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany

Cell +49(0)151 72009660, Email natasja.debruin@gmail.com

□ Current Address: Albemarle Catalysts Company B.V., Nieuwendammerkade 1–3, 1022 AB Amsterdam, The Netherlands

§§ Current Address: Pharma Holland Consultancy, Matrix III Building, Science Park 402, 1098 XH Amsterdam, The Netherlands

‡ Current Address: TNO, Utrechtseweg 48, 3704 HE Zeist, The Netherlands

‡‡ Current Address: Arizona Chemical B.V., Transistorstraat 16, 1322 CE Almere, The Netherlands

□□ Current Address: Enza Zaden, Haling 1/E, 1602 DB Enkhuizen, The Netherlands

‡‡‡ Current Address: Ace Pharmaceuticals BV, Schepenveld 41, 3891 ZK Zeewolde, The Netherlands

‡‡‡‡ Current Address: Sandoz BV, Veluwezoom 22, 1327 AH Almere, The Netherlands

□□□ Current Address: SILS/University of Amsterdam, Sciencepark 904, 1098 XH Amsterdam, The Netherlands

Download English Version:

<https://daneshyari.com/en/article/7299063>

Download Persian Version:

<https://daneshyari.com/article/7299063>

[Daneshyari.com](https://daneshyari.com)